The SA Journal Diabetes & Vascular Disease Vol 11 No 4 (November 2014)

24 / 44

158 VOLUME 11 NUMBER 4 • NOVEMBER 2014
REVIEW SA JOURNAL OF DIABETES & VASCULAR DISEASE
case-control study. Lancet 2004; 364: 937–952.
S0140-6736(04)17018-9
29. Wingard DL, Barrett-Connor E, Criqui MH, et al. Clustering of heart disease risk
factors in diabetic compared to nondiabetic adults. Am J Epidemiol 1983; 117:
19–26.
30. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and
12-yr cardiovascular mortality for men screened in the Multiple Risk Factor
Intervention Trial. Diabetes Care 1993; 16: 434–444.
10.2337/diacare.16.2.434
31. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in
non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes
Study (UKPDS: 23). Br Med J 1998; 316: 823–828. 10.1136/
bmj.316.7134.823
32. Adler AI, Stevens RJ, Neil A, et al. UKPDS 59: hyperglycemia and other potentially
modifiable risk factors for peripheral vascular disease in type 2 diabetes.
Diabetes Care 2002; 25: 894–899.
33. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin
improves prognosis of diabetic patients with coronary heart disease. A subgroup
analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care
1997; 20: 614–620.
34. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of
angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes
mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286–289.
35. Yusuf S, Sleight P, Pogue J, et al . Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart
Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:
145–153.
36. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia
in type 2 diabetes: a patient-centered approach. Position statement of the
American Diabetes Association (ADA) and the European Association for the
Study of Diabetes (EASD). Diabetologia 2012; 55:1577–1596.
org/10.1007/s00125-012-2534-0
37. American Diabetes Association. Standards of Medical Care in Diabetes.Diabetes
Care 2012; 35(suppl 1): S11–S63.
38. NICE. Type 2 Diabetes – newer agents. Clinical Guidelines 87. 1–49. 2009.
NICE.
39. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular
disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393.
40. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial
intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591.
41. British Cardiac Society. Joint British Societies’ guidelines on prevention of
cardiovascular disease in clinical practice. British Hypertension Society, Diabetes
UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association, and
JBS 2. Heart 2005; 91(suppl v): v1–v52.
42. Perk J, De BG, Gohlke H, et al. European Guidelines on cardiovascular disease
prevention in clinical practice (version 2012). The Fifth Joint Task Force of the
European Society of Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (constituted by representatives of nine societies
and by invited experts). Developed with the special contribution of the European
Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J
2012; 33: 1635–16701.
43. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–31421.
44. Framingham Heart Study. About the Framingham Heart Study. The National
Heart, Lung and Blood Institute and Boston University 2013. Available at: http://
[Last accessed 24 June
2013]
45. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile.
A statement for health professionals. Circulation 1991; 83: 356–362. http://
dx.doi.org/10.1161/01.CIR.83.1.356
46. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value
of the Framingham cardiovascular risk equation and the UKPDS risk engine
for coronary heart disease in newly diagnosed type 2 diabetes: results from
a United Kingdom study. Diabet Med 2005; 22: 554–562.
org/10.1111/j.1464-5491.2005.01494.x
47. McEwan P, Williams JE, Griffiths JD, Bagust A, Peters JR, Hopkinson P, Currie CJ.
Evaluating the performance of the Framingham risk equations in a population
with diabetes. Diabet Med 2004; 21: 318–323.
j.1464-5491.2004.01139.x
48. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE and
DECODE do not provide reliable cardiovascular risk estimates in type 2 diabetes.
Diabetes Care 2007; 30: 1292–1293. dc06-1358
49. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for
cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;
113: 791–798. 105.548206
50. Cohen JC, Boerwinkle E, Mosley TH, Jr, et al . Sequence variations in PCSK9, low
LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:
1264–1272.
51. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-
density lipoprotein cholesterol beginning early in life on the risk of coronary heart
disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012; 60: 2631–
2639.
52. Nambi V, Ballantyne CM. "Risky business": ten years is not a lifetime. Circulation
2009; 119: 362–364.
53. Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical
atherosclerosis in younger adults with low short-term but high lifetime estimated
risk for cardiovascular disease: the coronary artery risk development in young
adults study and multi-ethnic study of atherosclerosis. Circulation 2009; 119:
382–389.
54. Marma AK, Berry JD, Ning H, et al . Distribution of 10-year and lifetime predicted
risks for cardiovascular disease in US adults: findings from the National Health and
Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes
2010; 3:8–14.
55. Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM. Lifetime risk and
years lived free of total cardiovascular disease. J Am Med Assoc2012; 308: 1795–
1801.
56. Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D’Agostino RB Sr. Lifetime
risk of cardiovascular disease among Individuals with and without diabetes
stratified by obesity status in the Framingham Heart Study. Diabetes Care 2008;
31: 1582–1584.
57. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and
performance. Diabetologia 1991; 34: 877–890.
58. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly
presenting type 2 diabetic patients and the association with risk factors for
cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–317.
59. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2
diabetic patients and their association with different clinical and biochemical risk
factors. Diabetes Res 1990; 13: 1–11.
60. Staessen JA, Thijisq L, Fagard R, et al. Effects of immediate versus delayed
antihypertensive therapy on outcome in the Systolic Hypertension in Europe
Trial. J Hypertens 2004; 22: 847–857.
200404000-00029
61. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering
in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.
org/10.1056/NEJMoa0802743
62. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and
vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:
2560–2572.
63. DuckworthW, Abraira C, Moritz T, et al. Glucose control and vascular complications
in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139. .
org/10.1056/NEJMoa0808431
64. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of
cardiovascular disease through glycemic control in type 2 diabetes: A meta-
analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604–
612.
65. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of
intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–
1589.
66. Lehto S, Ronnemaa T, Haffner SM, et al . Dyslipidemia and hyperglycemia predict
coronary heart disease events in middle-aged patients with NIDDM. Diabetes
1997; 46: 1354–1359. diab.46.8.1354
67. Fruchart JC, Sacks FM, Hermans MP, et al . The Residual Risk Reduction Initiative:
a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc
Dis Res 2008; 5: 319–335.
68. YounisNN,SoranH,SharmaR,etal.Small-denseLDLandLDLglycation inmetabolic
syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc
Dis Res 2010; 7: 289–295.
69. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-
density lipoproteins to oxidative modification in subjects with the atherogenic
lipoprotein phenotype, pattern B. Am J Med 1993; 94: 350–356. .
org/10.1016/0002-9343(93)90144-E